Jacobs, Tom G.Mumbiro, VivianTembo, JohnEgbe, Franklin N.Moraleda, Cintados Anjos Botas Beca, Laize SilviaPassanduca, AlfeuKakooza, LawrenceDomínguez Rodríguez, Sara2026-10-262026-10-262026-04-13Jacobs, T. G., Mumbiro, V., Tembo, J., Egbe, F. N., Moraleda, C., Beca, L. S. D. A. B., Passanduca, A., Kakooza, L., Chitsamatanga, M., Nduna, B., Bramugy, J., Tagarro, A., Chhaganlal, K. D., Mutesi, S., Mark, N. L., Bwakura-Dangarembizi, M., Namuzizya, N., Ballesteros, A., Dominguez-Rodríguez, S., … Manukyan, L. (2026). Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: A sub-study of the EMPIRICAL randomised controlled trial. eClinicalMedicine, 94, 103899. https://doi.org/10.1016/j.eclinm.2026.1038992589-5370https://hdl.handle.net/11268/17512Cytomegalovirus (CMV) is a major unrecognised cause of morbidity and mortality in infants living with HIV. Valganciclovir, an oral prodrug of ganciclovir, treats CMV in immunocompromised patients, but pharmacokinetic data in infants living with HIV are lacking. This study evaluated exploratory valganciclovir pharmacokinetic and pharmacodynamic outcomes in infants with severe HIV-associated pneumonia.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Biocienciasjournal article10.1016/j.eclinm.2026.103899open accessVirologíaInmunologíaPediatríaGoal 3: Ensure healthy lives and promote well-being for all at all ages